No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
KURA240517C20000
- 2.40
- +0.79+49.07%
15min DelayClose May 17 15:58 ET
2.60High2.40Low
2.60Open1.61Pre Close2 Volume9 Open Interest20.00Strike Price500.00Turnover1458.44%IV3.52%PremiumMay 17, 2024Expiry Date2.17Intrinsic Value100Multiplier0DDays to Expiry0.23Time Value100Contract SizeAmericanOptions Type0.7338Delta0.0757Gamma7.52Leverage Ratio-11.0458Theta0.0000Rho5.51Eff Leverage0.0010Vega
Intraday
- 5D
- 1D
News
Buy Rating Affirmed for Kura Oncology Amidst Promising Ziftomenib Trials and Strategic Advantages
Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug
Kura Oncology (KURA) said Tuesday it completed the enrollment of 85 patients in the phase 2 segment of the clinical trial for potential leukemia drug Ziftomenib. The study evaluates Ziftomenib's effec
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Tourmaline Bio (TRML)
Express News | Kura Oncology Inc: Topline Data Expected in Early 2025
Express News | Kura Oncology Inc: Completes Enrollment in Registration-Directed Trial of Ziftomenib in Npm1-Mutant Aml
Estimating The Intrinsic Value Of Kura Oncology, Inc. (NASDAQ:KURA)
Key Insights Kura Oncology's estimated fair value is US$19.69 based on 2 Stage Free Cash Flow to Equity Current share price of US$21.07 suggests Kura Oncology is potentially trading close to its fai
Comments
20
Insider selling at Kura Oncology with no purchases in past year could concern investors. More ideally, insider ownership percentage would be higher. Yet, implications aren't set in stone, consider other company-specific risks.
Read more